Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

6,000

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

October 30, 2019

Study Completion Date

November 28, 2019

Conditions
Cancer of Cervix
Interventions
BIOLOGICAL

Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]

HPV vaccination in an alternative schedule for MSM of 1 dose (M0).

BIOLOGICAL

Two dose

HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6)

OTHER

Control group

HPV vaccination at 12 months

BIOLOGICAL

2 dose vaccination over 6 month

2-dose HPV vaccination regimen over a 6-month period (M0,6)

Trial Locations (1)

62270

Instituto Nacional de Salud Publica, Cuernavaca

All Listed Sponsors
collaborator

Universidad Nacional Autonoma de Mexico

OTHER

collaborator

National Council of Science and Technology, Mexico

OTHER

lead

Instituto Nacional de Salud Publica, Mexico

OTHER

NCT05149248 - Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study | Biotech Hunter | Biotech Hunter